News
Like

Boehringer Ingelheim’s EMPA-REG OUTCOME® long-term trial improves understanding of type 2 diabetes and cardiovascular diseases

July 10, 2017
210 Views
0 Comments
6 minutes read
Boehringer Ingelheim’s EMPA-REG OUTCOME® long-term trial improves understanding of type 2 diabetes and cardiovascular diseases

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, held an event to launch their latest innovative type 2 diabetes treatment in Lebanon. The event brought together leading experts in internal medicine and primary care physicians to highlight the latest innovative, convenient medical solutions and findings in cardiovascular implications related to type 2 diabetes.

The combination pill of Empagliflozin and Metformin hydrochloride – Synjardy is now available in Lebanon, to improve patient compliance and adherence to type 2 diabetes treatments and address the management of cardiovascular implications related to type 2 diabetes, reducing the relative risk of cardiovascular death, and offering more protection for patients, whilst reducing blood glucose, body weight and blood pressure in patients.

 

 

Today, healthcare professionals treating patients with type 2 diabetes in Lebanon can now prescribe this medication used to manage type 2 diabetes for those who are diabetic and have established cardiovascular disease. Despite advances in care, cardiovascular disease is still the number one cause of death among people with type 2 diabetes. In Lebanon, 47% of deaths are due to cardiovascular disease and is the primary reason for hospital admission due to a variety of social, economic and political factors.[2]

The risk of dying from cardiovascular disease is up to four times higher in people with diabetes[3]. Further, approximately one in two people with diabetes worldwide die due to cardiovascular disease.

Dr. Mounzer Saleh, Former President of the Lebanese Society of Endocrinology Diabetes and Lipids said, “The continuous change of lifestyle in Lebanon has led to striking increase in rates of type 2 diabetes. Lifestyle interventions and adherence to medications are central to disease prevention and management. Cardiovascular disease is the number one cause of death in people with type 2 diabetes worldwide and reducing cardiovascular risk, including death, is an essential component of diabetes care that was missing in older treatment interventions.’’

“The relationship between diabetes and CVD is complex; diabetes is a risk factor for CVD and conditions such as high blood pressure and obesity, that are more common in people with diabetes, are also risk factors for CV disease[4]. Reducing cardiovascular risk is an essential component of diabetes management and so patients need to be better educated on how to modify cardiovascular risk factors in order to offer the best chance of improving CVD outcomes.’’ said Dr. Antoine Sarkis, Professor in Cardiology at the Hotel dieu de France Hospital, Beirut, Lebanon.

Dr. Mounzer Saleh, also noted, “The complex interaction of risk factors for type 2 diabetes, makes it necessary to apply a holistic approach to the management of this chronic disorder. The latest treatments offered, JARDIANCE® & SYNJARDY®, are shifting the mind-set by not only focusing on lowering blood glucose levels in patients but also offering cardio-protection by reducing the relative risk of cardiovascular death by 38% on top of standard of care in adults with type 2 diabetes and established cardiovascular disease. Patient Knowledge of cardiovascular disease in Lebanon is scarce and so there is the need to work closely with the primary care service and government bodies, to obtain and align better outcomes for the population which has a high profile of cardiovascular risk factors.”

 

 

Moreover, Fouad Jeweidi, Country Head Levant, Boehringer Ingelheim said, “Robust research & development (R&D) has always been the guiding principle that has enabled us to discover and develop innovative methods to help support patients manage type 2 diabetes more effectively. We continue to invest in R&D excellence through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions, to ultimately make life better for all those affected by diabetes.”

Those who have type 2 diabetes have a higher risk of heart disease and stroke. Studies have shown that optimal blood glucose levels, along with the control of hypertension, weight loss and quitting smoking, are all necessary to reduce cardiovascular risks in type 2 diabetes patients.[5] In particular, those who have diabetes and hypertension, the risk of cardiovascular disease doubles. [6]  Regular check-ups can help patients living with type 2 diabetes and help to reduce adverse outcomes such as cardiovascular diseases associated with diabetes.

[1] Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovascular Diabetology. 2014;13:102

[2] http://www.who.int/nmh/countries/lbn_en.pdf

[3] Cardiovascular Disease & Diabetes | American Heart Association | http://www.heart.org/HEARTORG/Conditions/More/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp/#.WUJQ6U2wfmg

[4] World Heart Federation. Diabetes as a risk factor for cardiovascular disease. Available from: http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/ diabetes/

[5] Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus  I https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043722/

 

[6] Cardiovascular Disease & Diabetes I  http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp/#.VwEOm_l96XI

 

Editor_wr

1206 posts
0 comments
Do NOT follow this link or you will be banned from the site!